Literature DB >> 1972364

Congenital malformations and maternal consumption of benzodiazepines: a case-control study.

L Laegreid1, R Olegård, N Conradi, G Hagberg, J Wahlström, L Abrahamsson.   

Abstract

This study assessed potential teratogenic properties of benzodiazepine (BZD) intake during early pregnancy. Four neonatal diagnoses of congenital malformations (embryopathy and fetopathy, unspecified; unspecified congenital malformations of the nervous system; cleft palate and cleft lip; congenital malformations of the urinary tract) were selected. The authors' previous clinical experience had shown these diagnoses to be characteristic of infants born to mothers with excessive intake of BZD in early pregnancy. The selected diagnoses were present in 25 of 10,646 liveborn infants (2.3 per 1000) delivered by mothers living in the city of Gothenburg in 1985 and 1986. In 18 of these cases, it was possible to analyse maternal plasma, and eight samples (44 per cent) were found to be BZD-positive. Of 60 controls, two maternal blood samples (3 per cent) were positive for BZD. The difference is highly significant and suggests an association between these congenital malformations and BZD consumed during early gestation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972364     DOI: 10.1111/j.1469-8749.1990.tb16962.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  9 in total

1.  The use of central nervous system active drugs during pregnancy.

Authors:  Bengt Källén; Natalia Borg; Margareta Reis
Journal:  Pharmaceuticals (Basel)       Date:  2013-10-10

Review 2.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

Review 3.  Managing epilepsy in women of childbearing age.

Authors:  Pamela M Crawford
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  Antiepileptic drugs in women with epilepsy during pregnancy.

Authors:  Evan Gedzelman; Kimford J Meador
Journal:  Ther Adv Drug Saf       Date:  2012-04

5.  Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.

Authors:  L R Dolovich; A Addis; J M Vaillancourt; J D Power; G Koren; T R Einarson
Journal:  BMJ       Date:  1998-09-26

Review 6.  Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.

Authors:  Danielle Coppola; Leo J Russo; Robert F Kwarta; Ruana Varughese; Juergen Schmider
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  Pathogenesis of peroxisomal deficiency disorders (Zellweger syndrome) may be mediated by misregulation of the GABAergic system via the diazepam binding inhibitor.

Authors:  Rainer Breitling
Journal:  BMC Pediatr       Date:  2004-03-12       Impact factor: 2.125

8.  Midazolam inhibits chondrogenesis via peripheral benzodiazepine receptor in human mesenchymal stem cells.

Authors:  Yung-Ching Chen; King-Chuen Wu; Bu-Miin Huang; Edmund Cheung So; Yang-Kao Wang
Journal:  J Cell Mol Med       Date:  2018-03-07       Impact factor: 5.310

9.  Midazolam activates caspase, MAPKs and endoplasmic reticulum stress pathways, and inhibits cell cycle and Akt pathway, to induce apoptosis in TM3 mouse Leydig progenitor cells.

Authors:  Fu-Chi Kang; Shu-Chun Wang; Ming-Min Chang; Bo-Syong Pan; Kar-Lok Wong; Ka-Shun Cheng; Edmund Cheung So; Bu-Miin Huang
Journal:  Onco Targets Ther       Date:  2018-03-15       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.